文献速递妇科

Moore标准在多样化非试验性复发宫颈癌人群中的适用性

The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population.
PubMed 文献 · Gynecol Oncol · 2020-01-23

本研究回顾性分析了2012至2017年间诊断的274例复发宫颈癌患者,其中78例接受二线治疗,以评估Moore标准在非试验性、少数族裔为主人群中的预后价值。结果显示,高风险类别相比低中风险合并组,无进展生存期和总生存期的风险比显著更高,且低中风险组缓解率显著优于高风险组。黑人种族不影响生存或缓解率。

要点

  • Moore标准在非试验性复发宫颈癌人群中仍具预后价值。
  • 高风险类别患者PFS和OS风险显著高于低中风险合并组。
  • 黑人种族与更差的OS或PFS无关。

核心结论

  • Moore标准在多样化非试验性复发宫颈癌人群中具有预后价值。
  • 在非试验性人群中,黑人种族并不预测更差的OS或PFS。

研究设计与样本

  • 回顾性分析2012至2017年诊断的复发宫颈癌患者274例,其中78例接受二线治疗。
  • 人群以少数族裔为主:48例(61.5%)西班牙裔,22例(28.2%)黑人,7例(9%)非西班牙裔白人。

主要发现

  • 按Moore标准,低风险9例(11.5%),中风险48例(61.5%),高风险21例(26.9%)。
  • 高风险类别相比低中风险合并组,PFS风险比为5.24(p < .001),OS风险比为3.15(p = .002)。
  • 低中风险组缓解率为78.9%,高风险组为33.3%(p = .001)。
  • 黑人种族不影响生存或缓解率。

关键数值与推荐

  • 高风险类别PFS风险比5.24(p < .001),OS风险比3.15(p = .002)。
  • 低中风险组缓解率78.9%,高风险组33.3%(p = .001)。

临床怎么用

  • Moore标准可用于非试验性复发宫颈癌人群的预后分层。
  • 高风险类别患者预后较差,需更密切监测或强化治疗策略。
  • 黑人种族不应作为预后不良的独立预测因素。

局限性

  • 回顾性研究设计。
  • 样本量有限,二线治疗仅78例。
  • 单中心数据,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Moore Criteria is a prognostic index for recurrent or metastatic cervical cancer based on five factors. The criteria were developed retrospectively and validated prospectively in clinical trial populations receiving systemic chemotherapy (C). Our objective was to evaluate the prognostic value of the Moore Criteria in a largely minority, non-trial population at first recurrence. METHODS: Patients treated for recurrent cervical cancer diagnosed between 2012 and 2017 were analyzed retrospectively. Progression free survival (PFS) was defined from the date of recurrence to date of second recurrence. Overall survival (OS) was defined from the date of recurrence to date of death. RESULTS: Of 274 patients identified, 78 were treated in the second line. 48 (61.5%) were Hispanic, 22 (28.2%) were black, and 7 (9%) were white non-Hispanic. By Moore criteria, 9 patients (11.5%) were classified as low-risk, 48 (61.5%) as moderate risk, and 21 (26.9%) as high-risk. 53 patients (67.9%) received C, and 25 (32.1%) received other treatment modalities without C. The high-risk category carried a significantly higher hazard ratio for both PFS (5.24, p < .001) and OS (3.15, p = .002) compared with the low- and intermediate-risk combined group. The low- and intermediate-risk groups demonstrated 78.9% response rate, compared with 33.3% in the high-risk category (p = .001). Black race did not affect survival or response rate. CONCLUSION: The Moore Criteria carries prognostic value across a diverse recurrent cervical cancer population outside of the clinical trial setting. Our data suggest that in a non-trial population, black race is not predictive of worse OS or PFS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jordan SE, Schlumbrecht M, George S, et al. The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population. Gynecol Oncol. 2020. PMID: 31983517. doi:10.1016/j.ygyno.2020.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。